What's new

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised

Apr 28, 2025 - 16:14
 0
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised
Read More

Tags:

Previous Article

Management Board meeting on possible renewal of Executive Director’s mandate

Next Article

Trump Tariffs Prompt Slump in Shipments to US Ports

Related Posts

Business process description for certificates of medici...

Apr 22, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024

Opinion/decision on a Paediatric investigation plan (PI...

Apr 25, 2025  0

Qualification opinion for artificial intelligence-based...

Apr 22, 2025  0